STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM

Their core work

Radboudumc is a leading Dutch university medical center in Nijmegen that combines patient care with translational biomedical research. They specialize in clinical trials, biomarker discovery, immunotherapy, and precision medicine across areas including rare diseases, neurodegenerative disorders, diabetes, and cancer. Their research spans from molecular-level understanding (microbiome, genetics, epigenetics) to large-scale clinical validation and data-driven diagnostics. They are particularly strong in bridging preclinical findings to clinical application, running multi-center trials and building European disease-specific research networks.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Radboudumc focused heavily on traditional clinical trials, biomarker identification, stress-related disorders, and disease-specific interventions like iron chelation for Parkinson's and immunotherapy for lung cancer. From 2019 onward, their portfolio shifted markedly toward microbiome research, artificial intelligence, precision medicine, and translational neuroscience — reflecting a pivot from hypothesis-driven clinical studies toward data-driven, systems-level approaches. The emergence of AI, digital pathology, and vaccination-related work signals a modernization of their research toolkit and a broadening of their translational ambitions.

Radboudumc is rapidly integrating AI and computational methods into their clinical research strengths, making them an increasingly attractive partner for projects combining medical data with machine learning.

How they like to work

Radboudumc operates as both a project leader and a trusted consortium partner, coordinating 30 of their 91 H2020 projects (33%) — a high coordination rate for a university medical center. They thrive in large, multi-country consortia (844 unique partners across 51 countries), indicating they are experienced at managing complex international collaborations. Their network breadth suggests they are a hub organization rather than a niche specialist, comfortable integrating into diverse research teams while also capable of driving project strategy.

With 844 unique consortium partners spanning 51 countries, Radboudumc has one of the most extensive collaboration networks among European medical centers. Their reach is truly global, extending well beyond the EU into Africa (SURG-Africa) and encompassing both academic and industry partners across the health research landscape.

What sets them apart

Radboudumc combines the clinical infrastructure of a major university hospital with deep research capacity in immunology, neuroscience, and rare diseases — and is now layering AI and digital pathology on top of that foundation. Their 33% coordination rate and EUR 145M in H2020 funding demonstrate they can lead ambitious European projects, not just contribute. For consortium builders, they offer a rare combination: clinical trial execution capability, large patient cohorts, and growing computational expertise, all within a single institution.

Highlights from their portfolio

• PERISCOPE
  Coordinated a EUR 3.6M pertussis vaccine biomarker discovery project bridging systems vaccinology with regulatory science — one of their largest coordinated efforts.
• Solve-RD
  EUR 3.6M participation in the flagship European rare disease initiative connecting all European Reference Networks to solve undiagnosed cases through data-driven approaches.
• Eat2beNICE
  Coordinated an interdisciplinary EUR 1.5M project linking nutrition, gut microbiome, and behavioral disorders — exemplifying their shift toward systems-level, cross-domain research.